Suchergebnisse - "Podzamczer, Daniel"

PubPharm (28)

1

Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69)

enthalten in: Current HIV research | 2022

von Tiraboschi, J. | Prieto, P. | Saumoy, M. | +7

2

Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2021

von Berenguer, J. | Díez, C. | Martín-Vicente, M. | +21

3

Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Imaz, A. | Tiraboschi, J. | Niubó, J. | +14

4

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis : week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The lancet. HIV | 2021

von Ogbuagu, O. | Ruane, P. | Podzamczer, D. | +118

ErratumIn: Lancet HIV. 2021 Dec;8(12):e734. - PMID 34571044

5

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection : week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

enthalten in: The lancet. HIV | 2020

von Orkin, C. | DeJesus, E. | Sax, P. | +20

CommentIn: Lancet HIV. 2020 Jun;7(6):e374-e375. - PMID 32504568

6

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

enthalten in: AIDS (London, England) | 2020

von Orkin, C. | Eron, J. | Rockstroh, J. | +9

7

Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40)

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2019

von Imaz, A. | Niubó, J. | Cottrell, M. | +6

8

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate : a pooled analysis of 26 clinical trials

enthalten in: AIDS (London, England) | 2019

von Gupta, S. | Post, F. | Arribas, J. | +21

9

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1 : 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Ward, D. | Brar, I. | +12

CommentIn: Lancet HIV. 2018 Jul;5(7):e336-e337. - PMID 29925488

10

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults : a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

enthalten in: The lancet. HIV | 2018

von Winston, A. | Post, F. | DeJesus, E. | +14

CommentIn: Lancet HIV. 2018 Apr;5(4):e156-e157. - PMID 29475803